Category Archive: CSI News

Jul 25

History of heart failure indicates poor survival post-CABG

n a study published online July 13, 2016 in JAMA Cardiology, a history of heart failure (HF) was an important risk factor for poor short-term and long-term outcomes after CABG regardless of preoperative ejection fraction (EF). Reduced EF more than doubled the risk of early death after CABG. All-cause mortality 30 days after surgery was …

Continue reading »

Jul 24

Assessing the clinical profile and prognosis in patients with heart failure with recovered ejection fraction

A recent study evaluated whether patients with heart failure who recover left ventricular ejection fraction (Rec-HF) have a distinct clinical profile and prognosis in contrast to those with heart failure and reduced left ventricular ejection fraction or heart failure and preserved left ventricular ejection fraction. The results printed in the journal of Cardiology showed that …

Continue reading »

Jul 16

Long sedentary time increases risk of cardiovascular disease

A meta-analysis of prospective cohort studies found a nonlinear association with cardiovascular disease (CVD) such as coronary heart disease, myocardial infarction, stroke, and CVD-related death, suggesting that 10 hours a day might be a critical threshold. Compared with low levels of sedentary time (median 2.5 hours per day), intermediate levels (median 7.5 hours per day) …

Continue reading »

Jul 12

Analyzing the risk of atherosclerotic cardiovascular disease in individuals with familial hypercholesterolemia

Recently, an analysis was conducted in the individuals of the United States with a heterozygous familial hypercholesterolemia (FH) phenotype to determine the long-term risk of coronary heart disease (CHD) and total atherosclerotic cardiovascular disease (ASCVD). The FH phenotype was defined by a low-density lipoprotein (LDL) cholesterol concentration of ≥ 190 mg/dl while the referent value …

Continue reading »

Jul 12

Mortality and tachyarrhythmic episodes of variant angina with and without aborted sudden cardiac death

A multicenter retrospective analysis that assessed the long-term mortality and ventricular tachyarrhythmic events of variant angina with and without aborted sudden cardiac death revealed remarkably higher incidence of cardiac death in patients with aborted sudden cardiac death than in those who did not experience it. Moreover, during the follow up period, the rate of cardiac …

Continue reading »

Jul 07

Men are at greater risk of sudden cardiac death than women

Results from the long-running Framingham Heart Study published June 29, 2016 in the Journal of the American Heart Association says that men have at least twice the risk of dying from sudden cardiac death (SCD) than women, at all ages. Those with greater aggregate risk factor burden, or blood pressure level alone had a higher …

Continue reading »

Jul 04

Role of 2D speckle-tracking echocardiography in identifying left atrial strain in heart failure with preserved ejection fraction

Two-dimensional speckle-tracking echocardiography (2D-STE) has recently emerged as a useful tool for quantifying left atrium deformation dynamics. The current study published in the Herz Journal assessed the use of this tool in diagnosing heart failure with preserved ejection fraction as this syndrome is associated with impaired left atrial volume and function. The results established the …

Continue reading »

Jul 03

Family history biggest predictor of cardiac events in people with psoriasis

People with psoriasis are more likely to suffer myocardial infarction and stroke when they have a family history of cardiovascular problems, says a new Danish study reported in the Journal of the American Academy of Dermatology, online June 7. And, psoriasis was not found to be associated with a higher risk of MI or stroke …

Continue reading »

Jul 02

Bortezomib-based treatment improves survival in patients with cardiac amyloidosis

First-line treatment with the proteasome inhibitor bortezomib (Velcade, Millennium Pharmaceuticals) plus dexamethasone and an alkylating agent (BDex+AA) improves survival in patients with symptomatic heart failure due to amyloid light-chain (AL) amyloidosis, a rapidly fatal disease. After multivariable adjustment, patients receiving BDex+AA as their initial regimen had a 20% lower mortality risk than those receiving other …

Continue reading »

Jul 01

FDA Advisory Committee narrowly okay empagliflozin cardiovascular mortality claim

The Endocrinologic and Metabolic Drugs Advisory Committee voted 12-11 on June 28 that the data in the EMPA-REG OUTCOME study provided substantial evidence to establish that empagliflozin, sodium-glucose cotransporter-2 (SGLT-2), reduced cardiovascular mortality in the population studied, those with type 2 diabetes and established cardiovascular disease.

Older posts «